TOKYO -- Top Japanese drugmaker Takeda Pharmaceutical will sell some Asian prescription and over-the-counter products to South Korean biotechnology company Celltrion for up to $278 million, in the latest move to focus its business portfolio and cut debt.
The transaction, expected to conclude this year, covers 18 products sold mainly in Australia, Hong Kong, Macao, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand, Takeda said Thursday.
